Page 16«..10..15161718..3040..»

Category Archives: MS Treatment

Calculated Treatment Response Score May Help Choose Between MS Therapies – Neurology Advisor

Posted: Published on November 28th, 2020

A treatment response score consisting of a combination of age, sex, relapses in the previous year, disease duration, and Expanded Disability Status Scale (EDSS) could help determine which patients with multiple sclerosis (MS) would benefit from glatiramer acetate or interferon beta-1 (IFN-1a), according to study results published in Neurology. Continue reading

Posted in MS Treatment | Comments Off on Calculated Treatment Response Score May Help Choose Between MS Therapies – Neurology Advisor

Clinical observation experience of a pediatric patient with primary progressive multiple sclerosis in the Moscow office for the treatment of children…

Posted: Published on November 28th, 2020

This article was originally published here Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(10):45-50. Continue reading

Posted in MS Treatment | Comments Off on Clinical observation experience of a pediatric patient with primary progressive multiple sclerosis in the Moscow office for the treatment of children…

Superoxide dismutase (SOD), advanced oxidation protein products (AOPP), and disease-modifying treatment are related to better relapse recovery after…

Posted: Published on November 28th, 2020

This article was originally published here Neurol Sci. 2020 Nov 26. Continue reading

Posted in MS Treatment | Comments Off on Superoxide dismutase (SOD), advanced oxidation protein products (AOPP), and disease-modifying treatment are related to better relapse recovery after…

Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis – DocWire News

Posted: Published on November 28th, 2020

This article was originally published here Neurol Ther. 2020 Nov 26 Continue reading

Posted in MS Treatment | Comments Off on Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis – DocWire News

Treatment Start to Full Effect of Immunotherapies for MS – Medscape

Posted: Published on November 28th, 2020

Izanne Roos1,2, Emmanuelle Leray3, Federico Frascoli4, Romain Casey58, J. William L. Brown9, Dana Horakova10, Eva K Continue reading

Posted in MS Treatment | Comments Off on Treatment Start to Full Effect of Immunotherapies for MS – Medscape

Inflammatory Activity and Treatment Response in Pediatric Compared to Adult Multiple Sclerosis: A Pilot, Retrospective and Observational Study of the…

Posted: Published on November 28th, 2020

This article was originally published here Acta Med Port. 2020 Nov 24. Continue reading

Posted in MS Treatment | Comments Off on Inflammatory Activity and Treatment Response in Pediatric Compared to Adult Multiple Sclerosis: A Pilot, Retrospective and Observational Study of the…

MediciNova Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Published…

Posted: Published on November 28th, 2020

LA JOLLA, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) were published in Multiple Sclerosis Journal. Continue reading

Posted in MS Treatment | Comments Off on MediciNova Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Published…

Informing the Development of a Digital Health Platform Through Universal Points of Care: Qualitative Survey Study – DocWire News

Posted: Published on November 28th, 2020

JMIR Form Res. 2020 Nov 26;4(11):e22756. doi: 10.2196/22756. Continue reading

Posted in MS Treatment | Comments Off on Informing the Development of a Digital Health Platform Through Universal Points of Care: Qualitative Survey Study – DocWire News

Early Use of Ocrevus Best for Slowing PPMS Progression, Long-term… – Multiple Sclerosis News Today

Posted: Published on November 28th, 2020

Early and continuous use ofOcrevus(ocrelizumab) significantly slows disability progression and delays the time until wheelchair reliance in people with primary progressive multiple sclerosis (PPMS), new Phase 3 data spanning more than six years show. Findings fromthe ORATORIO trial, comparing immediate use with a two-year delay, support Ocrevus sustained and long-term benefits, and highlight gains realized through earlier treatment initiation in PPMS patients Continue reading

Posted in MS Treatment | Comments Off on Early Use of Ocrevus Best for Slowing PPMS Progression, Long-term… – Multiple Sclerosis News Today

MS News That Caught My Eye Last Week: Typing Patterns and MS… – Multiple Sclerosis News Today

Posted: Published on November 28th, 2020

This is an interesting concept that makes sense. Like the nine-hole peg test that some neurologists use to test finger dexterity, and like some apps that attempt to measure this, monitoring how quickly, and in what manner I can move my fingers might allow a physician to track the progression of my disease. It could be done remotely and frequently Continue reading

Posted in MS Treatment | Comments Off on MS News That Caught My Eye Last Week: Typing Patterns and MS… – Multiple Sclerosis News Today

Page 16«..10..15161718..3040..»